关键信息
-
基因名
SLC22A1LS
- 应用
-
别名
Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene B protein. Organic cation transporter-like protein 2 antisense protein. Solute carrier family 22 member 1-like antisense protein. Solute carrier family 22 member 18 antisense protein. p27-Beckwith-Wiedemann region 1 B. p27-BWR1B
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8N1D0
-
表达区间
1-150 aa
-
氨基酸序列
MRCAEGAWWFSPDGPAGSAASIWPAEGAEGLPGQLGRDRLEVVYSVPDNVPGQNGSRRPLVCKITGKCLSVCSEENAKAGGCSAFPLLLSQLGARMTGREHAHKGPELTTPDSGLPRPPNPALAGFRALAQHSPPLGTSTPSAVLLSAAT
-
分子量
41.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
SLC22A1 (Solute Carrier Family 22 Member 1), also known as OCT1 (Organic Cation Transporter 1), is a critical membrane protein involved in the transport of organic cations, including various drugs and endogenous compounds, across cell membranes. Research into the recombinant expression of SLC22A1 has gained significant attention due to its pivotal role in pharmacogenomics and drug metabolism. Variations in the SLC22A1 gene impact the transport efficiency and pharmacokinetics of numerous therapeutics, which can result in variable drug responses among individuals. Recombinant SLC22A1 proteins are essential for studying the functional properties of this transporter, enabling insights into substrate specificity, transport mechanisms, and the effects of genetic polymorphisms. Understanding these factors is crucial for optimizing drug therapies and developing personalized medicine approaches. Additionally, the study of SLC22A1 may provide valuable information regarding drug-drug interactions and toxicity, as many clinically relevant drugs are substrates of this transporter. By producing and characterizing recombinant SLC22A1 proteins, researchers can advance our understanding of its biological roles and therapeutic implications, ultimately contributing to improved drug efficacy and safety profiles in clinical settings.
